Study of Cannabidiol Oral Solution for Lennox-Gastaut Syndrome
This study is looking into how well Cannabidiol Oral Solution (CBD-OS) works as an add-on treatment for adults with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy. Researchers want to see if gradually increasing the dose of CBD-OS can help reduce seizures. You might be able to join if you are an adult (18 years or older) with a confirmed LGS diagnosis, have had seizures recently, and haven't used CBD-OS in the last three months. The study will consider it a success if a significant number of participants see their major motor seizures reduced by 50% or more over 28 days by the end of the 24-week treatment period. The current status of this study is unclear, but it plans to enroll about 40 participants.
- Study design
- This is a Phase 3b/Phase 4 interventional study, meaning it's testing a treatment that has already shown some promise. It plans to enroll about 40 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at the end of the 24-week treatment period, but further follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
At a glance
Conditions
NCT07728097
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Louisiana State University Health Sciences Center New Orleans
New Orleans, Louisianano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequencyEnd of Treatment Period, Week 24